6E5N

Solution structure of human Myosin VI isoform 3 (1050-1131) in complex with Clathrin light chain a (46-61)

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
2	3D 1H-15N NOESY	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
3	2D 1H-13C HSQC	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
4	3D 1H-13C NOESY	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
5	2D 1H-15N HSQC	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
9	3D 1H-15N NOESY	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
8	2D 1H-13C HSQC	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
7	3D 1H-13C NOESY	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
6	3D HNCO	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 700
10	3D HNCACB	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
12	3D HNCO	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
11	3D HNCACB	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
13	half-filtered 3D 1H-13C NOESY	0.36 mM [U-13C; U-15N] Myosin VI 1050-1131, 0.36 mM None Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850
14	half-filtered 3D 1H-13C NOESY	0.4 mM None Myosin VI 1050-1131, 0.4 mM [U-13C; U-15N] Clathrin Light Chain Alpha 46-61	95% H2O/5% D2O	50 mM NaCl, 20 mM NaPO4 mM	6.5	760 mmHg	283.2	Bruker AVANCE III 850

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	850
2	Bruker	AVANCE III	700

NMR Refinement
Method	Details	Software
simulated annealing		X-PLOR NIH

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	300
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin		Bruker Biospin
2	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	processing	NMRDraw		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
4	peak picking	XEASY		Bartels et al.
5	chemical shift assignment	XEASY		Bartels et al.
6	geometry optimization	TALOS		Cornilescu, Delaglio and Bax
7	structure calculation	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore
8	refinement	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.